September 2016 drtp0916_CV.jpg
The role of the community pharmacy team in assisting patients receiving oral anticancer medicationsThe goal of this activity is to educate the community pharmacy team about oral anticancer medications.
Way Back in 1982: Predicting pharmacy’s futureOccasionally, it can be interesting to learn what pharmacists and other insiders foresee as the industry’s future
The importance of a pharmacist’s consultation for lactating mothersThe rate of breastfeeding has reached over 75% in the U.S. The goal set by Healthy People 2020 is 82%. The Surgeon General has released a “call to action” that promotes breastfeeding for every mother who wishes to do so.
Do Clothes Make the Pharmacist?People are looking--and judging.
Medicare drug spending spike shows need for genericsAn exclusive Associated Press report found that Medicare’s spending on certain drugs soared by 85% in two years.
New center aims to increase pharmacists’ valueHelping pharmacists perform at the top of their licenses and be reimbursed for services such as medication therapy management (MTM) are among the goals of the National Community Pharmacist Association’s (NCPA) Innovation Center.
Pharmacist interventions boost adherence for minoritiesPharmacist intervention is one primary way that adherence to cholesterol-lowering medications can be improved in minority neighborhoods, a recent study found.
Are You Safe at Work?Retail pharmacies are in the news a lot these days. Unfortunately, it is not the kind of news anyone wants to hear.
New Mexico—a frontier still breaking new groundNew Mexico's state motto is “The Land of Enchantment,” but it might also be dubbed the The Land of Opportunity. Pharmacists here are increasingly breaking barriers to deliver frontline, provider care services in an environment that fosters innovations for the profession, students, and patients.
Starting your own pharmacyThese pharmacists forged their own paths.
PBM giants cut drug expensesWhen Express Scripts and CVS Health announced their 2017 formularies on August 1, a common theme emerged among the healthcare giants: several blockbuster drugs will be removed from both companies’ formularies and lower-cost options such as biosimilars are being embraced.
Pharmacists and the battle over medical foodsCommunity pharmacists are caught in the middle of a battle between patients and their health insurers over how the federal government defines medical foods and how patients are paying for them.
Health-system pharmacists embrace medication standardization campaignCompletion of Phase I of ASHP’s Standardize 4 Safety initiative is fast approaching.
Study: Biosimilars as safe as branded drugsNew study finds that biosimilar medications for arthritis and other diseases areas safe and effective as their brand-name counterparts.
Oral Anticoagulant Safety, Apixaban, Statins and VTEAccording to a recent report from the Institute of Safe Medication practices (ISMP), FDA received 34,765 adverse drug event reports for oral anticoagulants in 2015.
New dosage form for migraine treatmentFDA approved Onzetra Xsail (Avanir Pharmaceuticals Inc.)— a fast-acting, low-dose sumatriptan dry powder formulation for the acute treatment of migraine with or without aura in adults.
Risky antibiotic use threatens patientsPatients are willing to use antibiotics without contacting a medical professional, according to a study published in Antimicrobial Agents and Chemotherapy.
FDA expands its authority over tobacco productsAccording to FDA and other sources, tobacco use is the single largest preventable cause of disease and death in the United States.
A product for every hair-care needAmericans spend billions of dollars on products to address specific hair and scalp concerns each year—whether that be color, condition, or appearance.
A product for every hair-care needAmericans spend billions of dollars on products to address specific hair and scalp concerns each year—whether that be color, condition, or appearance.
Long-term safety of glycopyrrolate: A randomized study of COPD patientsGlycopyrrolate bromide is a quick-onset long-acting muscarinic antagonist bronchodilator with FDA approval for use as maintenance treatment of COPD. Seebri Neohaler is approved for use at a dose of 15.6 ug inhaled twice daily.
What executives must know to combat rising drug spendIn today’s healthcare landscape, few things better define the role of a managed healthcare executive than managing the industry’s constant changes.